Skip to main content
SpringerLink
Log in

Helicobacter pylori infection and peptic ulcer disease

  • Chapter
Proton Pump Inhibitors

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 378 Accesses

Abstract

At the stage when peptic ulcers appeared to become clinically controlled by more and more potent acid inhibitory agents, the traditional concept of ulcer pathogenesis was turned upside down by the discovery of a microorganism specialized to infect the human gastric mucosa. Helicobacter pylori infection is now recognized as the predisposing key factor and has assigned to the gastric acid a contributory though important role in gastric and duodenal ulcerogenesis. The discovery of this bacterium has reopened the chapters of gastric physiology and pathophysiology and has substantially modified the clinical management of peptic ulcer disease by offering the anti-H. pylori therapy as the definitive cure for the great majority of patients suffering from gastric and duodenal ulcers. The new classification of peptic ulcers attains to a clear distinction of H. pylori-positive ulcers or ulcers of other and less frequent etiologies (Tab. 1), thereby addressing the proper management for each entity. Management now consists of antibiotics in addition to acid-suppressive agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bizzozero G (1893) Über die schlauchförmigen Drüsen des Magendarmkanals und die Beziehung ihres Epithels zu dem Oberflächenepithel der Schleimhaut. Arch mikr Anat 82-152

    Google Scholar 

  2. Salomon H (1896) Über das Spirillum des Säugetiermagens und sein Verhalten zu den Belegzellen. Centralbl f Bakt 19: 433–442

    Google Scholar 

  3. Doenges JL (1939) Spirochetes in the gastric glands of Macacus rhesus and of man without related disease. Arch Pathol 27: 469–477

    Google Scholar 

  4. Palmer ED (1954) Investigation of the gastric mucosa spirochetes of the human. Gastroenterology 27: 218–220

    PubMed  CAS  Google Scholar 

  5. Warren JR (1983) Unidentified curved bacili on gastric epithelium in active chronic gastritis. Lancet I: 1273–1275

    Google Scholar 

  6. Marshall BJ (1983) Unidentified curved bacili on gastric epithelium in active chronic gastritis. Lancet I: 1273–1275

    Google Scholar 

  7. Rauws EAJ, Tytgat GNJ (1990) Cure of duodenal ulcer associated with eradication of Helicobacterpylori. Lancet 335: 1233–1235

    Article  PubMed  CAS  Google Scholar 

  8. Malfertheiner P, Bode G (1993) Helicobacter pylori and the pathogenesis of duodenal ulcer disease. Europ J Gastroenterol Hepatol 5 (Suppl): 51–58

    Google Scholar 

  9. Tytgat GNJ, Lee A, Graham DJ, Dixon MF, Rokkas T (1993b) The role of infectious agents in peptic ulcer disease. Gastroenterol Int 6: 76–89

    Google Scholar 

  10. Sipponen P (1992) Natural history of gastritis and its relationship to peptic ulcer disease. Digestion 51 (Suppl 1): 70–75

    Article  PubMed  Google Scholar 

  11. Schubert TT, Bologna SD, Nensey Y et al. (1993) Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med 94: 413–418

    Article  PubMed  CAS  Google Scholar 

  12. Neri M, Susi D, Bovani I, Laerza F, Mezzeti A, Cuccurullo F (1994) Bacterial mucosal infiltration in Helicobacter pylori-associated gastritis: histological and clinical consequences. Am J Gastroenterolog 89: 1801–1805

    CAS  Google Scholar 

  13. Khulusi S, Mendall MA, Patel P, Levy J, Northfield TC (1994) Is there a quantifiable difference in H. pylori infection density between DU and non-DU patients? (Abstract) Gastroenterology 106: A106

    Google Scholar 

  14. Bayerdörffer E, Miehlke S, Lehn N, Manes GA, Sommer A, Höchter W, Hatz R, Stolte M (1993) Chronic type B gastritis as an important denominator of peptic ulcer healing. Eur J Gastroenterol Hepatol 5 (Suppl 3)

    Google Scholar 

  15. Graham DY (1994) Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 89: 1137–1139

    PubMed  Google Scholar 

  16. Stolte M, Bethke B (1990) Elimination of H. pylori under treatment with omeprazole. Gastroenterology 28: 271

    CAS  Google Scholar 

  17. Logan RPH, Walker MM, Misiewicz JJ et al (1995) Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36: 12

    Article  PubMed  CAS  Google Scholar 

  18. Levi S, Beardshall K, Haddad G, Playford R, Gosh P, Calam J (1989) Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1: 1167–1168

    Article  PubMed  CAS  Google Scholar 

  19. McColl KEL, El-Omar E (1994) Effect of H. pylori infection on gastrin and gastric acid secretion. In: RH Hunt, GNJ Tytgat (eds): Helicobacter pylori. Basic Mechanisms to Clinical Cure. Kluwer, Dordrecht, 245

    Chapter  Google Scholar 

  20. Moss SF, Calam J (1993) Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 34: 888

    Article  PubMed  CAS  Google Scholar 

  21. Moss SF, Legon S, Bishop AE et al (1992) Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 340: 930

    Article  PubMed  CAS  Google Scholar 

  22. Odum I, Petersen HD, Andersen IB, Hansen BF, Rehfeld JF (1994) Gastrin and somatostatin in Helicobacter pylori infected antral mucosa. Gut 35: 615–618

    Article  PubMed  CAS  Google Scholar 

  23. Olbe L, Hamlet A, Dalenbäck J, Fändriks L (1996) A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 110: 1386–1394

    Article  PubMed  CAS  Google Scholar 

  24. Hamlet A, Olbe L (1996) The influence of Helicobacter pylori infection on postprandial duodenal acid load and duodenal bulb pH in humans. Gastroenterology 111: 391–400

    Article  PubMed  CAS  Google Scholar 

  25. McColl KEL, Fullarton GM, Chittajallu R, El Nujumi AM, Macdonald AMI, Dahill SW, Hilditch TE (1991) Plasma gastrin, daytime intragastric pH and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer patients. Scand J Gastroenterol 26: 339–346

    Article  PubMed  CAS  Google Scholar 

  26. El-Omar E, Penman I, Dorrian CA, Ardill JES, McColl KEL (1993) Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 34: 1060–1065

    Article  PubMed  CAS  Google Scholar 

  27. Kreiss C, Blum AL, Malfertheiner P (1995) Peptic ulcer pathogenesis. Curr Opin Gastroenterol 11 (Suppl 1): 25–31

    Article  Google Scholar 

  28. Noah LA, Rolf TM, Bosma NB et al (1993) Gastric metaplasia and Helicobacter pylori infection. Gut 34: 1510

    Article  Google Scholar 

  29. Carrick J, Lee A, Hazell S, Ralston M, Daskalopoulos G (1989) Campylobacter pylori, duodenal ulcer and gastric metaplasia: possible role of functional heterotopic tissue in ulcerogenesis. Gut 30: 790–797

    Article  PubMed  CAS  Google Scholar 

  30. Bode G, Malfertheiner P, Mader U, Stanescu A, Ditschuneit H (1991) Fine structure of active and healed duodenal ulcer. Am J Gastroenterol 86: 179–186

    PubMed  CAS  Google Scholar 

  31. Malfertheiner P, Halter F (1994) Peptic ulcer pathogenesis. Year in Helicobacter pylori. Curr Opin Gastroen 30-34

    Google Scholar 

  32. Khulusi S, Badve S, Patel P, Lloyd R, Marrero JM, Finlayson C, Mendall M, A., North-field TC (1996) Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid and ulceration. Gastroenterology 110: 452–458

    Article  PubMed  CAS  Google Scholar 

  33. Blaser MJ (1992) Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 102: 720–727

    PubMed  CAS  Google Scholar 

  34. Crabtree JE, Peichl P, Wyatt JL, Stachl U, Lindley IJ (1993) Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 37: 65–70

    Article  PubMed  CAS  Google Scholar 

  35. Crowe SE, Alvarez L, Dytoc H, Hunt RH, Muller M, Sherman P et al (1995) Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 108: 65–74

    Article  PubMed  CAS  Google Scholar 

  36. Dunn BE (1993) Pathogenic mechanisms of Helicobacter pylori. Gastroenterology Clin North Am 22: 43–57

    CAS  Google Scholar 

  37. Karttunen R (1991) Blood lymphocyte proliferation, cytokine secretion and appearance to T cells with activation surface markers in cultures with Helicobacter pylori. Clin Exp Immunol 83: 396–400

    Article  PubMed  CAS  Google Scholar 

  38. Hatz R, Bayerdörffer E, Lehn N, Enders G (1994) Immune response in Helicobacterpylori infection: implications for treatment of gastroduodenal disease. Clin Immunother 2: 295–306

    Article  Google Scholar 

  39. Rosam AC, Wallace JL, Whittle BJR (1986) Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature 319: 54–56

    Article  PubMed  CAS  Google Scholar 

  40. Smoot DT, Mobley HLT, Chippendale GR, Lewinson JF, Resau JH (1990) Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infect Immun 58: 1992–1994

    PubMed  CAS  Google Scholar 

  41. Goggin PM, Marrero JM, Spychal RT, Jackson PA, Corbishley CM, Northfield TC (1992) Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication. Gasterolology 103: 1486–1490

    CAS  Google Scholar 

  42. Mauch F, Bode G, Ditschuneit H, Malfertheiner P (1993) Demonstration of a phospholipidrich zone in the human gastric epithelium damaged by Helicobacter pylori: Gastroenterology 105: 1698–1704

    PubMed  CAS  Google Scholar 

  43. Hills BA (1993) Gastric mucosal barrier: evidence for Helicobacter pylori in gastric surfactant and deriving protection from it. Gut 38: 2071–2080

    Google Scholar 

  44. Figura N, Guglielmetti A, Rossolino A, Barberi A, Cusi G, Musmanno RA et al (1989) Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol 27: 225–226

    PubMed  CAS  Google Scholar 

  45. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchina G et al (1993) Molecular characterisation of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 90: 5791–5795

    Article  PubMed  CAS  Google Scholar 

  46. Cover TL, Blaser MJ (1992) Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 267: 10570–10575

    PubMed  CAS  Google Scholar 

  47. Tummuru MK, Sharma SA, Blaser MJ (1995) Helicobacter pylori cag C, a homolog of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Gastroenterology A246

    Google Scholar 

  48. Peek RM, Miller GG, Tham KT, Perez-Perez GI, Zhao XM, Atherton JC et al (1995) Heightened cytokine expression and inflammatory response in vivo to cag A+ Helicobacter pylori strains. Lab Invest 73: 760–770

    PubMed  CAS  Google Scholar 

  49. Atherton JC (1997) The clinical relevance of strain types of Helicobacter pylori. Gut 40: 701–703

    Article  PubMed  CAS  Google Scholar 

  50. Blaser MJ (1995) Intrastrain differences in Helicobacter pylori: a. key question in mucosal damage. Ann Med 27: 559–563

    Article  PubMed  CAS  Google Scholar 

  51. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A (1996) cag a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 93: 14648–14653

    Article  PubMed  CAS  Google Scholar 

  52. Van Doom L-J, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, De Boer W, Quint W (1998) Clinical relevance of the cag A, vac A and ice A status of Helicobacter pylori. Gastroenterology 115: 58–66

    Article  Google Scholar 

  53. Malaty HM, Engstrand M, Pedersen NL, Graham DY (1994) Helicobacter pylori infection: genetic and environmental influences. Ann Intern Med 120: 982–986

    PubMed  CAS  Google Scholar 

  54. Cowan WK (1973) Genetics of duodenal and gastric ulcer. Clin Gastroenterol 2: 539–546

    Google Scholar 

  55. Borén T, Falk P, Roth KA, Larson G, Normark S (1993) Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 262:1892–1895

    Article  PubMed  Google Scholar 

  56. Azuma T, Konishi J, Tanaka Y, Hirai M, Ito S, Kato T, Kohli Y (1994) Contribution of HLA-DQA gene to host’s response against Helicobacter pylori. Lancet 343: 542–543

    Article  PubMed  CAS  Google Scholar 

  57. Forbes GM, Glaser ME, Cullen DJE, Warren JR, Christiansen KJ, Marshall BJ et al (1994) Duodenal ulcer treated with Helicobacter pylori eradication: seven year follow-up. Lancet 343: 258–260

    Article  PubMed  CAS  Google Scholar 

  58. Huang JQ, Wilkinson JM, Hunt R H (1997) Antimicrobials accelerate healing of duodenal ulcer (DU) when given with proton pump inhibitors (PPI) or H2-receptor antagonists (H2RA): A meta-analysis. Gut 41: A93

    Article  Google Scholar 

  59. Graham DY, Hepps KS, Ramirez FC et al (1993) Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28: 939–942

    Article  PubMed  CAS  Google Scholar 

  60. Labenz J, Börsch G (1994) Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 55: 19–23

    Article  PubMed  CAS  Google Scholar 

  61. Rokkas T, Karameris A, Mavrogeorgis A et al (1995) Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 41: 1–4

    Article  PubMed  CAS  Google Scholar 

  62. Jaspersen D, Koerner T, Schorr W et al (1995) Helicobacterpylori eradication reduces the rate of rebleeding in ulcer haemorrhage. Gastrointest Enclosc 41: 5–7

    Article  CAS  Google Scholar 

  63. Santander C, Gravalos RG, Cedenillay AG, Cantero J, Pajares JM (1996) Antimicrobial therapy for Helicobacter pylori infection vs long-term maintenance antisecretion treatment in the prevention of recurrent haemorrhage from peptide ulcer: prospective nonran-domized trail of 125 patients. Am J Gastroenterol 91: 1549–1552

    PubMed  CAS  Google Scholar 

  64. Riemann JF, Schilling D, Schauwecker P, Wehlen G, Dorlars D, Kohler B, Maier M (1997) Cure with omeprazole plus amoxicillin vs long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding. Gastrointest Endosc 46: 299–304

    Article  PubMed  CAS  Google Scholar 

  65. NIH Consensus Conference (1994) Helicobacter pylori in peptic ulcer disease. NTH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272(1): 65–69

    Article  Google Scholar 

  66. Malfertheiner P, Nilius M Bismuth preparations. In: CS Goodwin, BW Worsley (eds): Helicobacter pylori: biology and clinical practice. CRC Press, Boca Raton. 1993:351–364

    Google Scholar 

  67. Hackelsberger A, Malfertheiner P (1996) A risk-Benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug Safety 15(1): 30–52

    Article  PubMed  CAS  Google Scholar 

  68. Rauws EAJ, Langenberg W, Houthoff H J et al (1988) Campylobacterpyloridis associated chronic active antral gastritis: a prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 94: 33–40

    PubMed  CAS  Google Scholar 

  69. Malfertheiner P (1993) Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol 28 (Suppl 196): 34–37

    Article  Google Scholar 

  70. Bianchi Porro G, Parente F, Lazzaroni M (1993) Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut 34: 466–469

    Article  Google Scholar 

  71. Axon ATR (1992) Helicobacter pylori therapy: effect on peptic ulcer disease. J Gastroenterol Hepatol 6: 131–137

    Article  Google Scholar 

  72. Chiba N, Rao BV, Rademaker JW, Hunt RH (1992) Meta-analysis of the efficacy of antibiotic therapy in eradicating. Helicobacter pylori. Am J Gastroenterol 87: 1716–1727

    CAS  Google Scholar 

  73. Graham DY, Lew GM, Malaty HM et al (1992) Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102: 493–496

    PubMed  CAS  Google Scholar 

  74. Burget DW, Chiverton SG, Hunt RH (1990) Is there an optimal degree of acid suppresion for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 99: 345–351

    PubMed  CAS  Google Scholar 

  75. Jones DB, Howden CW, Burget DW et al (1987) Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 28: 1120–1127

    Article  PubMed  CAS  Google Scholar 

  76. Howden CW, Burget DW, Hunt RH (1994) Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol 29 (Suppl 201): 79–82

    Article  Google Scholar 

  77. Nakao M, Malfertheiner P (1998) Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 3(1): 21–27

    Article  PubMed  CAS  Google Scholar 

  78. Suerbaum S, Leying H, Klemm K et al (1991) Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbio I Infect Dis 10: 92–93

    Article  CAS  Google Scholar 

  79. Iwahi T, Satoh H, Nakao M et al (1991) Lansoprazole, a novel benzimidazole proton pump inhibitor and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 35: 490–496

    Article  PubMed  CAS  Google Scholar 

  80. Unge P, Gad A, Gnarpe H et al (1989) Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol 24 (Suppl 167): 49–54

    Article  Google Scholar 

  81. Hui WM, Lam SK, Ho J et al (1991) Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci 36: 577–582

    Article  PubMed  CAS  Google Scholar 

  82. Rauws EA, Langenberg W, Bosma A et al (1991) Lack of eradication of Helicobacter pylori after omeprazole (letter). Lancet 337: 1093

    Article  PubMed  CAS  Google Scholar 

  83. Weil J, Bell GD, Powell K et al (1991) Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 5: 309–313

    Article  PubMed  CAS  Google Scholar 

  84. Louw JA, Zak J, Jaskiewicz K et al (1992) Omeprazole may clear but not eradicate H. pylori. Eur J Gastroenterol Hepatol 4: 481–485

    Google Scholar 

  85. Sherman P, Shames B, Loo V et al (1992) Omeprazole therapy for Helicobacter pylori infection. Scand J Gastroenterol 27: 1018–1022

    Article  PubMed  CAS  Google Scholar 

  86. Bugnoli M, Bayeli PF, Rappuoli R et al (1993) Inhibition of Helicobacterpylori urease by omeprazole. Eur J Gastroenterol Hepatol 5: 683–685

    Article  Google Scholar 

  87. Nagata K, Satoh H, Iwahi T et al (1993) Potent inhibitory action of gastric pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 37: 769–774

    Article  PubMed  CAS  Google Scholar 

  88. Axon ATR (1994) The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 29 (Supp 201): 16–23

    Article  Google Scholar 

  89. McGowan CC, Cover TL, Blaser MJ (1994) The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 107: 1573–1578

    Article  PubMed  CAS  Google Scholar 

  90. Ge Z, Hiratsuka K, Taylor DE (1995) Nucleotide sequence and mutational analysis indicate that two Helicobacter pylori genes encode a P-type ATPase and a cation binding protein associated with copper transport. Mol Microhiol 15: 97–106

    Article  CAS  Google Scholar 

  91. Wandall JH (1992) Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation and translocation of cytochrome b-245. Gut 33: 617–621

    Article  PubMed  CAS  Google Scholar 

  92. Gustavson LF, Kaiser JF, Mukherjee DX et al (1994) Evaluation of pharmakokinetic drug interactions between clarithromycin and omeprazole (abstract). Am J Gastroenterol 89:1373

    Google Scholar 

  93. Paulsen O, Höglund P, Walder M (1989) No effect of omeprazole-inducted hypoacidity on the bioavailability of amoxicillin or bacampicillin. Scand J Infect Dis 21: 219–223

    Article  PubMed  CAS  Google Scholar 

  94. Pommerien W, Braun M, Idström JP et al (1995) No interaction between omeprazole and amoxicillin during combination therapy in Helicobacter pylori positive healthy subjects (abstract). Gastroenterology 108: A194

    Article  Google Scholar 

  95. Bayerdörffer E, E,, Marines GA, Sommer A et al (1992) High dose omeprazole treatment combined with amoxicillin eradicates Helicobacer pylori. Eur J Gastroenterol Hepatol 4: 697–702

    Google Scholar 

  96. Bayerdörffer E, Mannes GA, Sommer A et al (1993) Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxicillin. Scand J Gastroenterol 28(Suppl 169): 19–25

    Article  Google Scholar 

  97. Bayerdörffer E, Miehlke S, Mannes GA et al (1995) Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108: 1412–1417

    Article  PubMed  Google Scholar 

  98. Labenz J, Gyene E, Rühl GH et al (1993) Omeprazole plus amoxicillin: efficacy of various treatment regimes to eradicate Helicobacter pylori. Am J Gastroenterol 88: 491–495

    PubMed  CAS  Google Scholar 

  99. Labenz J, Gyenes E, Rühl GH et al (1993) Amoxicillin plus omeprazole vs triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 34: 1167–1170

    Article  PubMed  CAS  Google Scholar 

  100. Labenz J, Rühl GH, Bertrams J et al (1994) Medium and high dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci 39: 1483–1487

    Article  PubMed  CAS  Google Scholar 

  101. Mannes GA, Bayerdörffer E, Hele C et al (1993) An increasing dose of omeprazole combined with amoxicillin increases the eradication rate of Helicobacter pylori (abstract). Gastroenterology 104(Suppl): A140

    Google Scholar 

  102. Goh KL, Peh SC, Parasakthi N et al (1994) Omeprazole 40 mg combined with amoxicillin alone or with amoxicillin and metronidazole in the eradication of Helicobacter pylori. Am J Gastroenterol 89: 1789–1792

    PubMed  CAS  Google Scholar 

  103. Collins R, Beattie S, O’Morain C (1993) High dose omeprazole plus amoxicillin in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 7:313–315

    Article  PubMed  CAS  Google Scholar 

  104. McCarthy CJ, Collins R, Beattie S, Hamilton H, O’Morain C (1993) Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. Aliment Pharmacol Ther 7: 463–466

    Article  PubMed  CAS  Google Scholar 

  105. Bell G, Powell K, Weil J et al (1991) Experience with omeprazole in combination with either amoxycillin or colloidal bismuth subcitrate in patients with metronidazole-resistant Helicobacter pylori. Eur J Gastroenterol Hepatol 3: 923–926

    Google Scholar 

  106. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdörffer E (1997) An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 11: 323–329

    Article  PubMed  CAS  Google Scholar 

  107. Pommerien W, Schultze V, Lembcke B et al (1995) Dose response of twice daily dosing of omeprazole combined with amoxicillin on H. pylori eradication in duodenal ulcer patients (abstract). Gastroenterology 108: A193

    Article  Google Scholar 

  108. Labenz J, Leverkus F, Borsch G (1994) Omeprazole plus amoxicillin for cure of Helicobacter pylori infection: factors influencing the treatment success. Scand J Gastroenterol 29: 1070–1075

    Article  PubMed  CAS  Google Scholar 

  109. Graham DY, Operkun AR, Klein PD (1993) Clarithromycin for the eradication of Helicobacterpylori. J Clin Gastroenterol 16: 292–294

    Article  PubMed  CAS  Google Scholar 

  110. Peterson WL, Graham DY, Marshall B et al (1993) Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 88: 1860–1864

    PubMed  CAS  Google Scholar 

  111. Logan RP, Gummett PA, Schaufelberger HD et al (1994) Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 35: 323–326

    Article  PubMed  CAS  Google Scholar 

  112. O’Morain C, Dettmer A, Rambow A et al (1994) and the Clarithromycin European H. pylori Study Group: Dual therapy with clarithromycin and omeprazole for the treatment of active duodenal ulcers (abstract). Am J Gastroenterol 89: A1384

    Google Scholar 

  113. Labenz J, Stolte M, Domian C et al (1995) High dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. Digestion 56: 14–20

    Article  PubMed  CAS  Google Scholar 

  114. Harris AV, Gummett PA, Logan RP et al (1995) Eradication of Helicobacter pylori with lansoprazole and clarithromycin. Aliment Pharmacol Ther 9: 201–204

    Article  PubMed  CAS  Google Scholar 

  115. Cayla R, Zerbib F, de Mascarel A et al (1994) High dose of lansoprazole in combination with amoxycillin and clarithromycin twice daily for H. pylori eradication: results of a pilot study (abstract). Am J Gastroenterol 94: A1367

    Google Scholar 

  116. Bazzoli F, Zagari RM, Fossi S et al (1994) Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 6: 773–777

    Article  Google Scholar 

  117. Jaup BH, Norrby A (1995) Low-dose, short term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gasteroenterol 90: 943–945

    CAS  Google Scholar 

  118. Labenz J, Stolte M, Rühl GH et al (1994) One week, low-dose triple therapy for the cure ofHelicobacter pylori infection. Eur J Gastroenterol Hepatol 7: 9–11

    Google Scholar 

  119. Moayyedi P, Sahay P, Tompkins DS et al (1995) Efficacy and optimum dose of omeprazole in a new 1-week-triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepato 7: 835–840

    CAS  Google Scholar 

  120. Adamek RJ, Szymanski C, Pfaffenbach B, et al (1995) Short term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection. Dtsch Med Wochenschr 120: 358–360

    Article  PubMed  CAS  Google Scholar 

  121. Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O’Morain C, Cooper BT, Kerr GD, Dixon MF, Langworthy H, Piper D et al (1997) One week triple therapy for Helicobacter pylori: a multicentre comparative study. Gut 41: 735–739

    Article  PubMed  CAS  Google Scholar 

  122. Lind T, Veldhuyzen van Zanten S, Unge P et al (1996) Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1: 138–144

    Article  PubMed  CAS  Google Scholar 

  123. Lind T, Megraud F, Unge P, Bayerdörffer E, O’Morain C, Spiller R, Veldhuyzen van Zanten S, Dev Bardhan K, Hellblom M, Wrangstadh M et al (1997) The MACH 2 study — the role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies — a randomised double-blind study; submitted

    Google Scholar 

  124. Megraud F (1994) H. pylori resistance to antibiotics. In: RH Hunt, GNJ Tytgat, Helicobacter pylori — basic mechanisms to clinical cure. Kluwer, Dordrecht, 570–583

    Google Scholar 

  125. Bayerdörffer E (1997) Is OAM giving satisfactory results? Astra Symposium Prague Proceedings; in press

    Google Scholar 

  126. De Boer W, Tytgat GNJ (1995) Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther 9: 633–638

    Article  PubMed  Google Scholar 

  127. The European Helicobacter pylori study group Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41(1): 8–13

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Magdeburg, Leipziger Str. 44, D-39120, Magdeburg, Germany

    Peter Malfertheiner

Authors
  1. Peter Malfertheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Centre for Gastroenterological Research, University of Göteborg, S-41345, Göteborg, Sweden

    Lars Olbe

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Malfertheiner, P. (1999). Helicobacter pylori infection and peptic ulcer disease. In: Olbe, L. (eds) Proton Pump Inhibitors. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8795-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8795-3_11

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9777-8

  • Online ISBN: 978-3-0348-8795-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation